Hospital

Individuals with COVID-19 who had not had a flu shot were up to 20% more likely to be admitted to the ICU and were up to 58% more likely to visit the emergency department.

White continued to discuss how being self-aware, using the right language, modeling behaviors that support belonging, and fostering an environment with psychological safety is the goal as a a health care provider.

In an interview with Pharmacy Times®and Directions in Oncology Pharmacy®, Chad Hatfield, PharmD, MHA, BCPS, chief pharmacy officer at UC Davis Medical Center, discussed how data analytics are used in oncology pharmacy practice.

Brexucabtagene autoleucel (Tecartus, Kite Pharma) is a cell-based gene therapy for the treatment of adult patients with mantle cell lymphoma who have not responded to or who have relapsed following other treatments.

A huge cost savings could be generated with the success of a hepatitis C vaccine.

In one program, hospital pharmacists received alerts whenever an antiretroviral was prescribed in the emergency department, enabling prompt action.

The FDA has granted enfortumab vedotin-ejfv both a regular approval and a new indication expansion for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received 1 or more prior lines of therapy.

Specialty pharmacists have the expertise and respect necessary to change the health care system while listening to patients’ needs and guiding them through difficult experiences.

The trial has successfully enrolled 17 patients with clear cell renal cell carcinoma and has reported that the drug is well tolerated at doses of up to 525 mg weekly.

Vaccinated individuals overall had large amounts of antibodies present compared to infected individuals, suggesting that vaccination both protects against becoming infected and reduces the likelihood of transmitting the virus to others.

The study analyzed nearly 4000 patients with these pathologies and 30,000 control individuals, examining the neurobiological basis for aggressive behavior.

In an interview with Pharmacy Times, Chris Zaleski, PharmD, RPh, said pharmacy technicians are essential pharmacy team members to prevent dispensing errors and enhance patient care.

Because viral clearance is compromised if HIV is allowed to replicate for an extended period of time—resulting in extensive damage to the immune system—controlling HIV with antiretroviral therapy may be critical to preventing this type of viral evolution in SARS-CoV-2 in patients with advanced HIV.

Despite the encouraging progression-free survival findings, data on overall survival resulted in a partial clinical hold instituted by the FDA.

Margetuximab-cmkb (Margenza) was approved in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which for metastatic disease.

The risk for developing the rare neurological condition are low following vaccination, with the FDA noting the benefits of vaccination far outweigh the potential risks.

The approval marks the first nonsteroidal mineralocorticoid receptor antagonist proven to significantly slow chronic kidney disease progression and reduce cardiovascular risk in individuals with chronic kidney disease associated with type 2 diabetes.

Results from the APOLLO trial showed a significant 37% reduction in the risk of progression or death, compared to pomalidomide and dexamethasone alone in patients with multiple myeloma.

Education and preparedness are essential for the treatment of this inherited disorder related to the musculosketal system.

This action follows a recently completed phase 2a clinical trial, which demonstrated that 100% of the 10 enrolled patients met the study's primary and secondary efficacy endpoints of clinical cure at end of treatment as well as sustained clinical cure with no recurrence of CDI when examined on a 28-day follow-up visit.

The FDA granted accelerated approval in 2019 to enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before or after surgery, or in a locally advanced or metastatic urothelial cancer setting.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the importance of the FDA’s expedited approval process for infigratinib in the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the implications of the DARE-19 trial results assessing dapagliflozin as a treatment for patients with type 2 diabetes hospitalized with COVID-19.

The companies say COVID-19 booster shots may be necessary, although the FDA and CDC have disagreed.

The data show that the maximum tolerated dose of rigosertib in combination with nivolumab was not reached in the 3 cohorts of the trial’s dose-escalation phase in patients with advanced KRAS-positive metastatic lung adenocarcinoma.

The preprint submitted by the company consists of a new analysis from blood samples obtained from a subset of participants in the phase 3 ENSEMBLE study.

The new results add to earlier findings from the EMPEROR-Reduced phase 3 trial, which found that empagliflozin reduced the combined relative risk of cardiovascular death or hospitalization for heart failure by 25% compared to placebo.

A retrospective case series published in JAMA Cardiology found that although there are rare instances of myocarditis—inflammation of the heart muscle—in younger men following COVID-19 vaccination, the greater risk for heart damage and death comes from COVID-19 infection.

The investigators also found that the risk of spreading disease may be lower amongst those with breakthrough infections.

The messages offered alternatives to these prescription drugs and offered education for providers that is designed to lead to a change in medication.